Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 11/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363452 | 1.00 | AHCY (0.64) | AHCYADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL6366274 | 0.87 | ADORA2A (0.54) | AHCYADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL384146 | 0.87 | ADORA2A (0.54) | AHCYADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL28719079 | 0.85 | AHCY (0.61) | AHCYADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL28719083 | 0.85 | AHCY (0.61) | AHCYADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL7593668 | 0.85 | AHCY (0.44) | AHCYADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL21999215 | 0.84 | AHCY (0.67) | AHCYADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL9703479 | 0.84 | AHCY (0.67) | AHCYADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL28509879 | 0.84 | AHCY (0.60) | AHCYADORA2AADORA1ALDH1A1CYP3A4 | |
| SCHEMBL465830 | 0.84 | CCNE1 (0.51) | AHCYADORA2AADORA1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110614-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4125936-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021194890-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2016-12-01 | — | — | US | claimed |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | EPIPHANY BIOSCIENCES, INC. | 2015-02-19 | — | — | US | claimed |
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| EP-1532157-A4 | NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES | METABASIS THERAPEUTICS INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-7214668-B2 | Phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. (US) | 2007-05-08 | — | — | US | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| WO-2004074503-A2 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | HOSER MARK J (GB) | 2004-09-02 | — | — | WO | claimed |
| US-20040157793-A1 | Modified nucleosides as antiviral agents | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2004-08-12 | — | — | US | claimed |
| WO-2004043402-A2 | MODIFIED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004037161-A2 | CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES | METABASIS THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | claimed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | claimed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | claimed |
| EP-0205826-B1 | PHOSPHONYLMETHOXYALKYL ADENINES FOR THE TREATMENT OF VIRUS DISEASES | Stichting REGA V.Z.W. (BE) | 1992-03-18 | — | — | EP | claimed |
| US-4724233-A | VIRICIDES | STICHTING REGA VZW (BE) | 1988-02-09 | — | — | US | claimed |
| EP-0205826-A2 | Phosphonylmethoxyalkyl adenines for the treatment of virus diseases | Stichting REGA V.Z.W. (BE) | 1986-12-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346287-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | AHCY 174/4885ADORA2A 68/4885ADORA1 409/4885 |
| US-20150050241-A1 | METHOD OF TREATING VIRAL INFECTIONS | IFNG, BCL9, GDA | AHCY 174/4885ADORA2A 68/4885ADORA1 409/4885 |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | AHCY 1461/4885ADORA2A 128/4885ADORA1 270/4885 |
| US-20040157793-A1 | Modified nucleosides as antiviral agents | PNP, SAMHD1, SLC29A1 | AHCY 417/4885ADORA2A 76/4885ADORA1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.